SCHEMBL16166392

SCHEMBL16166392

CON=Cc1cc(CC(C)=O)cc2c1N(CCCCl)CC2

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 11/20 0.32
ADRA1A P35348 11/20 0.32
ADRA1B P35368 11/20 0.32
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
ALPL P05186 1/20 0.30
ALPI P09923 1/20 0.30
MAPT P10636 1/20 0.30
ALPG P10696 1/20 0.30
MAPK1 P28482 1/20 0.30
APOBEC3A P31941 1/20 0.30
RECQL P46063 1/20 0.30
BLM P54132 1/20 0.30
KMT2A Q03164 1/20 0.30
RXFP1 Q9HBX9 1/20 0.30
APOBEC3G Q9HC16 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
DRD2 P14416 1/20 0.30
DRD1 P21728 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16166262 0.91 ADRA1D (0.32) ADRA1DADRA1AADRA1BDRD2DRD1
SCHEMBL16166560 0.89 MEN1 (0.33) ADRA1DADRA1AADRA1BKDM4EMEN1
SCHEMBL17502986 0.89 MEN1 (0.33) ADRA1DADRA1AADRA1BKDM4EMEN1
SCHEMBL16166451 0.85 KDM4E (0.33) ADRA1DADRA1AADRA1BKDM4EMEN1
SCHEMBL16166498 0.80 ADRA1D (0.33) ADRA1DADRA1AADRA1BMEN1MAPT
SCHEMBL16166144 0.75 CYP11B2 (0.33) ADRA1DADRA1AADRA1BKDM4EMEN1
SCHEMBL16171297 0.75 ADRA1D (0.35) ADRA1DADRA1AADRA1BDRD2DRD1
SCHEMBL16166555 0.70 ADRA1D (0.33) ADRA1DADRA1AADRA1BKDM4EMEN1
SCHEMBL16166556 0.70 ADRA1D (0.33) ADRA1DADRA1AADRA1BKDM4EMEN1
SCHEMBL20032558 0.69 ADRA1D (0.43) ADRA1DADRA1AADRA1BDRD2DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2984070-B1 N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES MANKIND PHARMA LTD (IN) 2018-01-17 EP claimed
US-9862681-B2 N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives MANKIND RESEARCH CENTRE (IN) 2018-01-09 US claimed
US-20160046577-A1 N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives MANKIND PHARMA LTD (IN) 2016-02-18 US claimed
EP-2984070-A1 N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES Mankind Research Centre (IN) 2016-02-17 EP claimed
CN-105102429-A N-haloalkylindoline intermediates, process and use in preparation of silodosin and derivatives thereof MANKIND RES CT 2015-11-25 CN claimed
WO-2014167507-A1 N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES MANKIND RESEARCH CENTRE (IN) 2014-10-16 WO claimed
US-10239833-B2 Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin MANKIND PHARMA LTD. (IN) 2019-03-26 US disclosed
US-20180111901-A1 Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin MANKIND PHARMA LTD. (IN) 2018-04-26 US disclosed
EP-2984070-B1 N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES MANKIND PHARMA LTD (IN) 2018-01-17 EP disclosed
US-9862681-B2 N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives MANKIND RESEARCH CENTRE (IN) 2018-01-09 US disclosed
US-20160046577-A1 N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives MANKIND PHARMA LTD (IN) 2016-02-18 US disclosed
CN-105102429-A N-haloalkylindoline intermediates, process and use in preparation of silodosin and derivatives thereof MANKIND RES CT 2015-11-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10239833-B2 Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin ADRA1D, ADRB1, ADRA1A ADRA1D 1/4885ADRA1A 3/4885ADRA1B 5/4885
US-20160046577-A1 N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives ADRA1D, ADRA1A, ADRB1 ADRA1D 1/4885ADRA1A 2/4885ADRA1B 4/4885
US-20180111901-A1 Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin ADRA1D, ADRA1A, ADRB1 ADRA1D 1/4885ADRA1A 2/4885ADRA1B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.